TAS

TAS, Tas or tas may refer to:

Organizations

People

Television, film, and music

Books

Tas (series)

The Tas series is a pair of children's science fiction novels written by Reginald Alec Martin, under the pseudonym of E. C. Eliott. The books were illustrated by A. Bruce Cornwell. They are set, at least at the beginning, at the Woomera Rocket Range in Australia.

Plot

Tas and his friends have adventures with rockets and spaceships.

Books

References

50th Airlift Squadron

The 50th Airlift Squadron is one of four operational flying Air Mobility Command squadrons currently stationed at Little Rock AFB in Jacksonville, Arkansas. The "Fightin' 5-0 along with their sister squadrons, the 41 AS, 53 AS, and the 61 AS, are assigned to the 19th Operations Group.

History

Activated in the summer of 1942 under I Troop Carrier Command and equipped with C-47 Skytrains. Trained in various parts of the eastern United States until the end of 1943. Deployed to French Morocco in May 1943 and assigned to Twelfth Air Force to support combat operations in the North African Campaign. Remained with Twelfth Air Force, moving to Tunisia and Sicily providing transport and resupply operations as well as casualty evacuation of wounded personnel in the Mediterranean Theater of Operations (MTO). Reassigned to IX Troop Carrier Command, Ninth Air Force in England during early 1944 as part of the build-up of Allied forces prior to the D-Day invasion of France.

Began operations by dropping paratroops into Normandy on D-Day (6 June 1944) and releasing gliders with reinforcements on the following day. The unit received a Distinguished Unit Citation and a French citation for these missions.

40th Airlift Squadron

The 40th Airlift Squadron is a United States Air Force unit based at Dyess Air Force Base, Abilene, Texas. The unit currently flies the new Lockheed Martin C-130J Super Hercules aircraft. Nicknamed the Screaming Eagles, it is one of the most decorated airlift units in the U.S. Air Force.

Origins

On 18 February 1942, the squadron was activated as the 40th Transport Squadron at Duncan Field, San Antonio, Texas under the control of the 317th Troop Carrier Group. Beginning with only a second lieutenant squadron commander and eight enlisted men, the squadron slowly took shape, and in about four months was full-sized. At this time it transferred to Bowman Field, Kentucky where it began flying the Douglas C-47 Skytrain. The pace of developments in World War II drove a rapid training and deployment schedule, and on 6 December 1942, the 40th moved to Laurinburg-Maxton Army Airfield, North Carolina to begin staging for its move to the Pacific. A few days later, the Squadron left North Carolina for the Mobile Air Depot, Alabama where it received thirteen new C-47s. After they checked out the airplanes, the squadron flew to California.

TAS5690

The TAS5690 is a 42-ton 12x12 special heavy duty truck and used by the People's Liberation Army of the People's Republic of China.

The truck is marketed by Taian Special Vehicle Manufactory as a general purpose heavy duty truck and mainly for military applications.

References

TAS-108

TAS-108, also known as SR16234, is a drug discovered by Masato Tanabe and under development by SRI International and Taiho Pharmaceutical. It is a steroid hormone that has shown signs of treating and preventing breast cancer, even in patients where tamoxifen has failed.

Development

Masato Tanabe's team at SRI has focused on the development of steroid hormones. A compound discovered in a previous SRI contract from the National Institute of Health showed potential – it acted like "anti-estrogen" in the breasts and uterus but like normal estrogen elsewhere in the body, and was more "tissue-selective". A contract was proposed to Taiho Pharmaceutical in July 1996, and within six years and slightly under $3 million (an unusually short amount of time), two new drugs were discovered and tested on people (particularly people for which tamoxifen has failed): SR16234 and SR16287.

The first of those, SR16234, also inhibited the growth of blood vessels angiogenesis and accelerated the death of cancer cells apoptosis and thus was particularly well suited to be an anti-cancer drug. As of August 2010, the drug had been through five Phase I and two Phase II studies, and Phase III studies are being planned.